SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Conditions:   Metastatic Pancreatic Adenocarcinoma;   Refractory Pancreatic Adenocarcinoma;   Stage IV Pancreatic Cancer AJCC v8 Interventions:   Biological: Nivolumab;   Radiation: Radiation Therapy;   Drug: TLR9 Agonist SD-101 Sponsors:   University of California, Davis;   National Cancer Institute (NCI);   Bristol-Myers Squibb;   Dynavax Technologies Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conditions:   Pancreatic Cancer;   Pancreatic Adenocarcinoma Interventions:   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Drug: FOLFIRINOX Sponsor:   Indiana University Withdrawn
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Pancreas | Pancreatic Cancer | Radiation Therapy | Research